Edition:
United States

Argos Therapeutics Inc (ARGS.OQ)

ARGS.OQ on NASDAQ Stock Exchange Global Market

0.16USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
882,137
52-wk High
$5.65
52-wk Low
$0.13

Latest Key Developments (Source: Significant Developments)

Argos Therapeutics Enters Into Agreement With Saint-Gobain Performance Plastics Corp
Tuesday, 28 Nov 2017 08:54am EST 

Nov 28 (Reuters) - Argos Therapeutics Inc ::ARGOS THERAPEUTICS - ‍ON NOV 22, ENTERED INTO A SATISFACTION AND RELEASE AGREEMENT WITH SAINT-GOBAIN PERFORMANCE PLASTICS CORP - SEC FILING.ARGOS THERAPEUTICS-UNDER AGREEMENT,CO AGREED TO MAKE, ISSUE & DELIVER TO SAINT-GOBAIN, AN UNSECURED CONVERTIBLE PROMISSORY NOTE IN AMOUNT OF $2.4 MLN‍​.ARGOS - ‍IN CONNECTION WITH DEAL, CO, SAINT-GOBAIN ENTERED INTO AMENDMENT TO DEVELOPMENT DEAL TO EXTEND TERM OF DEVELOPMENT DEAL TO DEC 31, 2019​.ARGOS THERAPEUTICS- UNDER AGREEMENT,CO AGREED TO MAKE, ISSUE & DELIVER TO SAINT-GOBAIN,CASH PAYMENT OF $500,000, 689,995 SHARES OF CO'S COMMON STOCK.  Full Article

Argos Provides Financial Update
Tuesday, 28 Nov 2017 08:00am EST 

Nov 28 (Reuters) - Argos Therapeutics Inc ::ARGOS PROVIDES FINANCIAL UPDATE.ARGOS THERAPEUTICS - ‍TKC PROPERTIES HAS, WITH ARGOS' FULL CONSENT, SUCCESSFULLY COMPLETED SALE OF FACILITY IN DURHAM COUNTY, NC TO A THIRD PARTY​.ARGOS THERAPEUTICS-RAISED ABOUT $6.8 MILLION NET PROCEEDS UNDER ITS AT-THE-MARKET STOCK ISSUANCE FACILITY WITH COWEN & CO SUBSEQUENT TO Q3 CLOSE ON SEPT 30​.ARGOS THERAPEUTICS - ‍IN CONNECTION WITH DEAL, CO ENTERED LEASE TERMINATION DEAL WITH TKC, TO WHICH CO RECEIVED CASH PROCEEDS OF ABOUT $1.8 MILLION​.ARGOS THERAPEUTICS INC - ‍COMPANY BELIEVES IT NOW HAS SUFFICIENT CASH TO EXECUTE ITS BUSINESS PLAN AT LEAST THROUGH JUNE 2018​.  Full Article

Argos reports third quarter financial results
Thursday, 9 Nov 2017 04:46pm EST 

Nov 9 (Reuters) - Argos Therapeutics Inc :Argos reports third quarter 2017 financial results and operational highlights.Qtrly loss per share $0.10 ‍​.  Full Article

Argos Therapeutics files for offering of 13.5 mln shares of common stock by Invetech
Friday, 3 Nov 2017 05:04pm EDT 

Nov 3 (Reuters) - Argos Therapeutics Inc :Argos Therapeutics files for offering of 13.5 million shares of common stock by Invetech Pty Ltd - SEC filing.  Full Article

Argos Therapeutics Q2 loss per share $ 0.21
Wednesday, 9 Aug 2017 05:04pm EDT 

Aug 9 (Reuters) - Argos Therapeutics Inc :Argos Therapeutics reports second quarter 2017 financial results and recent operational highlights.Qtrly net loss per share, basic and diluted $ 0.21.  Full Article

Argos reports immunogenicity results of AGS-004 in HIV program
Wednesday, 26 Jul 2017 08:00am EDT 

July 26 (Reuters) - Argos Therapeutics Inc ::Argos reports immunogenicity results of ags-004 in HIV program.Argos therapeutics- data from study of ags-004 dendritic cell therapy in patients treated during acute HIV infection; study achieved primary endpoint​.Argos therapeutics inc- ‍ags-004 was found to be well-tolerated, with no serious adverse events reported in study​.Argos therapeutics- study ‍results provide support for ongoing HIV eradication study in which ags-004 is being administered in combination with vorinostat.  Full Article

Argos Therapeutics announces $6 mln secured convertible note financing
Friday, 16 Jun 2017 08:00am EDT 

June 16 (Reuters) - Argos Therapeutics Inc -:Argos Therapeutics announces $6,000,000 secured convertible note financing.Argos Therapeutics Inc - ‍sale of note is expected to close on June 21, 2017​.Argos Therapeutics -entered note purchase agreement for sale of a secured convertible promissory note to pharmstandard international s.a. In private placement.  Full Article

Argos therapeutics provides update on ADAPT trial following meeting with FDA
Wednesday, 10 May 2017 08:00am EDT 

May 10 (Reuters) - Argos Therapeutics Inc :Argos provides update on its ADAPT trial following meeting with FDA.Argos Therapeutics Inc- FDA agreed with company's plan to continue trial in accordance with current protocol to 290 events.Argos Therapeutics - FDA agreed to review, protocol amendment to increase pre-specified number of events for primary analysis of OS beyond 290 events.Argos - submitted information on analysis of interim data to fda, met to discuss future direction of ADAPT trial, rocapuldencel-t development program.  Full Article

Argos Reports interim results of the ADAPT trial
Tuesday, 18 Apr 2017 04:05pm EDT 

April 18 (Reuters) - Argos Therapeutics Inc : :Argos reports interim results of the ADAPT trial and provides perspective on decision to continue the trial.Argos Therapeutics Inc- continues to analyze data from trial and plans to meet with fda in may 2017.Argos Therapeutics Inc- currently believes based on data it has reviewed that trial should be continued until completion.  Full Article

Argos Therapeutics says Keystone-Centennial II notifies it was terminating lease effective immediately
Thursday, 23 Mar 2017 04:54pm EDT 

Argos Therapeutics Inc - : On March 17, 2017 Keystone-Centennial II notified company that it was terminating lease effective immediately - SEC filing . In termination notice, landlord asserted that co was in default under lease due to nonpayment of invoices for up-fit costs .Company never occupied leased space.  Full Article

BRIEF-Argos Therapeutics Enters Into Agreement With Saint-Gobain Performance Plastics Corp

* ARGOS THERAPEUTICS - ‍ON NOV 22, ENTERED INTO A SATISFACTION AND RELEASE AGREEMENT WITH SAINT-GOBAIN PERFORMANCE PLASTICS CORP - SEC FILING